EZH2 and prostate cancer: ChIP-seq-based mapping of EZH2 binding and H3K27me3 in LNCaP-abl cells, a castration-resistant prostate cancer model, showed that approximately 90% of EZH2-bound regions overlap the expected H3K27me3; however, the remaining ~10% of so-called EZH2-“solo” peaks were found enriched in active histone marks (H3K4me2 and H3K4me3) and RNA Pol II, suggesting a potential role in gene activation [42].